Association for Creatine Deficiencies Welcomes New Board Member

​​The Association for Creatine Deficiencies (ACD) is welcoming Doctor Matthew Skelton as part of their Scientific Medical Advisory Board. Dr. Skelton joins Dr. Nicola Longo, Dr. Bruce Barshop, Dr. Sarah Young, and Dr. Denise Morita as distinguished advocates for Cerebral Creatine Deficiency Syndromes (CCDS).

“Dr. Skelton has done amazing work in the field of Creatine Transport Deficiency. He has developed and verified the behavioral makeup of the X-linked Creatine Transporter Deficiency (CTD) knockout mouse,” Remarked Linda Cooper, Director of Special Initiatives for ACD. “His work is extremely important to our CTD patient community and, with this mouse, Dr. Skelton's lab will be able to continue giving pertinent insight to understanding CTD while potentially helping in the quest for future treatments.” 

Matthew Skelton is an Assistant Professor at the Department of Pediatrics in the University of Cincinnati’s Division of Neurology at Cincinnati Children’s Hospital. He earned his PhD in Developmental Biology from the University of Cincinnati and completed a Postdoctoral Fellowship with Cincinnati Children’s Research Foundation. Skelton remarks, “I am excited to work with the ACD. We share a common goal of researching treatments and ultimately changing the lives of those affected by Cerebral Creatine Deficiencies.”

The focus of Dr. Skelton’s research work is to better understand what happens to brain cells that do not have creatine, and how these cells contribute to the cognitive deficits observed in the mice. His lab uses a variety of techniques, from molecular biology to electrophysiology to behavioral testing, to answer these questions. He has been NIH funded and authored over 45 peer-reviewed manuscripts. Dr. Skelton is a member of the Society for Neuroscience and the International Behavioral Neuroscience Society.

ACD’s Scientific Medical Advisory Board

About ACD: The Association for Creatine Deficiencies’ mission is to eliminate the challenges of CCDS through education, advocacy, and medical research. Because CCDS mimic symptoms of other medical conditions, patients are often misdiagnosed. Proper diagnosis and early intervention are critical to establish treatments needed to improve life quality and longevity for the CCDS patient. The ACD was established to raise awareness and education of CCDS among the medical community, as well as the general public, and to advocate on behalf of families and patients living with Cerebral Creatine Deficiency Syndromes. For more information regarding ACD, please visit http://www.creatineinfo.org.